Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab versus tocilizumab plus vitamin D for hyperinflammatory COVID-19
2020-001903-17Phase 3Active
- Sponsor
- Hospital Universitario de Móstoles
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in coronavirus disease 2019 (COVID-19) comparing Tocilizumab alone with Tocilizumab plus vitamin D (2 arms). Primary endpoint: Global survival rate. Started May 2020; status: active.
02
Drugs
tocilizumabvitamin d
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001903-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001903-17.